About Delinea: Delinea is a pioneer in securing human and machine identities through intelligent, centralized authorization, empowering organizations to seamlessly govern their interactions across the modern enterprise. Leveraging AI-powered intelligence, Delinea’s leading cloud-native Identity Security Platform
Role: Hybrid in Redwood City, CA. (Will consider Remote for the right candidate) Must have: Experience building large-scale prediction or optimization systems PubMatic is the leading AI-powered ad tech company delivering measurable advertising performance through an intelligent,
Role: Hybrid in Redwood City, CA, or New York, NY (Will consider Remote for the right candidate) Must have: Experience in performance advertising, programmatic bidding, or large-scale user-conversion optimization loops PubMatic is the leading AI-powered ad tech
About Zūm: Zūm is revolutionizing mass mobility with its Connected Mobility Experience ( Zūm CMX) system that connects and coordinates people, vehicles, and operations in real time. In the $50 billion student mobility market – the
SOLUTION ARCHITECT Job Description Summary: Summary of Duties: Provide overall project oversight on technical and architectural designs. Leverage a proven track record in delivering professional services engagements with increased complexity and demonstrate command of the Reltio
About Delinea: Delinea is a pioneer in securing human and machine identities through intelligent, centralized authorization, empowering organizations to seamlessly govern their interactions across the modern enterprise. Leveraging AI-powered intelligence, Delinea’s leading cloud-native Identity Security Platform
Build a safer world with us, one incident at a time. Ambient.ai is the category creator and leader in Agentic Physical Security. Powered by Ambient Pulsar, the first reasoning Vision-Language Model purpose-built for physical security, our
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)